Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 16/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409997 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL410290 | 1.00 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL406128 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL406715 | 0.81 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL4467979 | 0.80 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL716555 | 0.78 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL4454079 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 | |
| Bromide SCHEMBL382081 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL4564695 | 0.76 | ADORA2A (0.68) | ADORA2AADORA1ADORA2BADORA3 | |
| SCHEMBL411463 | 0.76 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119053347-A | Immune antigen specific IL-18 immunocytokine and uses thereof | 明峰治疗股份公司 | 2024-11-29 | — | — | CN | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2016-01-07 | — | — | US | claimed |
| EP-2408775-B1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2015-06-17 | — | — | EP | claimed |
| US-20120053191-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ALFASIGMA S.P.A. (IT) | 2012-03-01 | — | — | US | claimed |
| EP-2408775-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | claimed |
| WO-2010106145-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-23 | — | — | WO | claimed |
| WO-2025224598-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4604957-A1 | COMBINATIONS OF A SERD FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-08-27 | — | — | EP | disclosed |
| CN-120051280-A | Combination of SERD for treating cancer | 阿斯利康(瑞典)有限公司 | 2025-05-27 | — | — | CN | disclosed |
| WO-2024083716-A1 | COMBINATIONS OF A SERD FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-04-25 | — | — | WO | disclosed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2016-01-07 | — | — | US | disclosed |
| US-9133197-B2 | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-09-15 | — | — | US | disclosed |
| EP-2408775-B1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2015-06-17 | — | — | EP | disclosed |
| US-20120053191-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ALFASIGMA S.P.A. (IT) | 2012-03-01 | — | — | US | disclosed |
| EP-2408775-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106145-A1 | OXIDATED DERIVATIVES OF TRIAZOLYPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | ADORA2A 1801/4885ADORA1 3168/4885ADORA2B 2902/4885 |
| US-20120053191-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
| US-20250332300-A1 | HER2 TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | ERBB2, EGFR, ERBB3 | ADORA2A 2229/4885ADORA1 3482/4885ADORA2B 3053/4885 |
| US-20160002244-A1 | OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.